mgc pharmaceuticals (Seite 20)
eröffnet am 21.12.17 16:30:27 von
neuester Beitrag 02.04.24 08:34:50 von
neuester Beitrag 02.04.24 08:34:50 von
Beiträge: 1.257
ID: 1.269.872
ID: 1.269.872
Aufrufe heute: 1
Gesamt: 161.718
Gesamt: 161.718
Aktive User: 0
ISIN: AU0000326647 · WKN: A40A1Q
0,2335
EUR
-0,85 %
-0,0020 EUR
Letzter Kurs 08:18:08 Lang & Schwarz
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,5700 | +55,23 | |
| 0,7200 | +47,03 | |
| 5,4500 | +41,56 | |
| 1,0000 | +33,33 | |
| 119,40 | +29,92 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 13,800 | -13,86 | |
| 4,1900 | -14,49 | |
| 0,9235 | -16,88 | |
| 5,2500 | -19,23 | |
| 0,7500 | -48,28 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 71.940.417 von ThatstheWayItGoes am 08.07.22 08:36:424 Sekunden 😀👍
"South African Ethics Committee Approval Granted for the
Dose Finding Study of CimetrA™ on Patients Diagnosed with
COVID-19"
"The study to be undertaken in South Africa is an extension of the dosing study currently underway
in Israel, ... with interim analysis results due in the coming
weeks"
https://www.investi.com.au/api/announcements/mxc/1dd81df3-7b…
Dose Finding Study of CimetrA™ on Patients Diagnosed with
COVID-19"
"The study to be undertaken in South Africa is an extension of the dosing study currently underway
in Israel, ... with interim analysis results due in the coming
weeks"
https://www.investi.com.au/api/announcements/mxc/1dd81df3-7b…
"Launch of ZAM – Medical data App" voraussichtlich in Q3
"The App will not only provide
patients with instructions on how and when to take medication (per their medical practitioner’s
advice), but will also measure treatment progress, and have the ability for a qualified doctor to
prescribe alternative medication following a consultation."
https://www.investi.com.au/api/announcements/mxc/83f0d958-e4…
https://cabatech.com/why-caba/
"The App will not only provide
patients with instructions on how and when to take medication (per their medical practitioner’s
advice), but will also measure treatment progress, and have the ability for a qualified doctor to
prescribe alternative medication following a consultation."
https://www.investi.com.au/api/announcements/mxc/83f0d958-e4…
https://cabatech.com/why-caba/
CimetrATM Pre-clinical Trial Progress Report
https://www.investi.com.au/api/announcements/mxc/8d87d68b-48…
https://www.investi.com.au/api/announcements/mxc/8d87d68b-48…
Trading Spotlight
https://www.investi.com.au/api/announcements/mxc/fe54a713-10…
Successful Glioblastoma Pre-clinical Trial Results
Successful Glioblastoma Pre-clinical Trial Results
MGC's chief medical officer discusses the results of its recent dementia treatment trial
CogniCann© Phase II Clinical Trial Results
Key Highlights:
MGC Pharma’s recently completed Phase II Clinical Trial for its proprietary Dementia
treatment, CogniCann®, demonstrates full safety and preliminary efficacy profile.
The Clinical Trial results demonstrate the ability of CogniCann® to inhibit the deterioration in
the behaviour of patients with Dementia.
It is estimated that nearly 787,000 people in the UK, and 450,000 people in Australia, suffer
from Alzheimer’s disease, with approximately 78% of these having mild or moderate symptoms. In the top 4 European countries, this number is closer to 1 million, and is expected to grow by 15% by 20241.
https://www.investi.com.au/api/announcements/mxc/7b107f7c-7b…
Key Highlights:
MGC Pharma’s recently completed Phase II Clinical Trial for its proprietary Dementia
treatment, CogniCann®, demonstrates full safety and preliminary efficacy profile.
The Clinical Trial results demonstrate the ability of CogniCann® to inhibit the deterioration in
the behaviour of patients with Dementia.
It is estimated that nearly 787,000 people in the UK, and 450,000 people in Australia, suffer
from Alzheimer’s disease, with approximately 78% of these having mild or moderate symptoms. In the top 4 European countries, this number is closer to 1 million, and is expected to grow by 15% by 20241.
https://www.investi.com.au/api/announcements/mxc/7b107f7c-7b…
Antwort auf Beitrag Nr.: 71.624.529 von ahnungslos80 am 20.05.22 20:45:48Hat dem Kurs auch nichts gebracht.
Cannabis ist wohl nix für Börse.
Hab noch keinen Kurs steigen gesehen.
Cannabis ist wohl nix für Börse.
Hab noch keinen Kurs steigen gesehen.
Durchsuchen
